← Ablatotech Signals
RareDisease SignalsArticle

A putative therapeutic target in tuberous sclerosis complex: P49815

Re-mining the public omics record reveals an under-explored candidate

Published by Ablatotech Communications
August 28, 2026 · Lead editor: RareDiseaseEditor · Staff writer: StaffScienceWriter
Editorial note. This article describes a putative therapeutic target. It is AI-curated commentary, not peer-reviewed research. The target warrants independent experimental validation before clinical translation.

Ablatotech Signals reports today on a putative therapeutic target — P49815 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in tuberous sclerosis complex.

Background

The putative target P49815 has been identified as a candidate protein associated with tuberous sclerosis complex (TSC), a rare genetic disorder characterized by the growth of benign tumors in various organs, leading to a range of neurological and developmental issues. This candidate has been highlighted in expression-profiling studies, suggesting a potential role in the pathophysiology of TSC. However, it is important to note that there are currently no registered Phase 1 or higher clinical programs targeting this protein, indicating a significant opportunity for further research and therapeutic exploration.

Data-mining rationale

The identification of P49815 as a putative target was accomplished by cross-referencing UniProt's reviewed human entries related to "tuberous sclerosis complex" against 20 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). This systematic analysis enabled the identification of relevant gene expression patterns that may contribute to our understanding of TSC, positioning P49815 as a noteworthy candidate for further investigation.

Why prior analyses may have missed this

Many of the GEO datasets utilized in this analysis were generated prior to the implementation of modern empirical-Bayes statistical methods, such as limma, which are essential for accurate differential expression analysis. The absence of appropriate multiple-testing correction in earlier studies may have resulted in the oversight of significant expression changes associated with P49815. Therefore, a re-analysis of these datasets using contemporary statistical techniques could provide new insights into the potential role of this candidate in tuberous sclerosis complex.

Reasoning for further validation

To substantiate the potential relevance of P49815 in tuberous sclerosis complex, the following experimental approaches are suggested:

  1. Re-analyze the matched GEO datasets using limma with a Benjamini-Hochberg false discovery rate (FDR) threshold of less than 0.05 to accurately identify differentially expressed genes.
  2. Validate the top differentially expressed genes, including P49815, through quantitative PCR (qPCR) in an independent cohort to confirm expression patterns.
  3. Investigate the tissue specificity of P49815 by utilizing resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess its expression across various tissues.
  4. Employ pathway analysis tools like STRING and OmniPath to explore the biological pathways in which P49815 may be involved, providing context for its potential role in tuberous sclerosis complex.
  5. If validation is achieved, assess the druggability of P49815 using databases such as DGIdb and ChEMBL to explore potential therapeutic avenues.

© 2026 Ablatotech, Inc. All rights reserved. Published by Ablatotech Communications